{"id":915673,"date":"2025-12-03T10:34:00","date_gmt":"2025-12-03T15:34:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/"},"modified":"2025-12-03T10:34:00","modified_gmt":"2025-12-03T15:34:00","slug":"annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/","title":{"rendered":"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MALVERN, Pa., Dec.  03, 2025  (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California.<\/p>\n<p>The presentation builds on momentum from the Company\u2019s recent <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QH3EpIBC2VQ9nR_zjJKU8Yhl-tUPUwedGzOlxXh9D5Rn4L7hqsVD1N-2Dp0XFr_mrdcF6ydGVdl4Mf_bf9dB0iIyMi_TNU8rPlA6mVAHWI08IbUKHyUY-2ivyDNB4ftQEuIZF4zpOaF1MtIIcJEbjJh-9nXfjVfAKzVGxhd_OX3tpDcYV8LcU8heok-IH0kcPmLTWblAJgad0MSgFuT3B6eKavaGkf9mFS96_PGemYCGXLSpH7V32Xx3opfr1Q8IMJMz3DRX1o87Ad01uN6HsPtfwcfnpdFrdETkboJxJec=\" rel=\"nofollow\" target=\"_blank\">Phase 3 PD biomarker data<\/a>, showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntanetap also reduces tau biomarkers, which are known to increase with disease severity.<\/p>\n<p>The presentation will also debut a cross-study comparison of the completed trials, providing the most comprehensive look yet at cognitive outcomes across all tested indications by Annovis and highlighting the population that benefits most \u2013 patients with amyloid pathology. In both Parkinson\u2019s and Alzheimer\u2019s, individuals with biomarker-confirmed presence of amyloid experience the greatest cognitive gain following buntanetap. These findings further validate the drug\u2019s mechanism as a translational inhibitor of neurotoxic aggregating proteins and support the Company\u2019s next strategic steps.<\/p>\n<p>\n        <strong>Presentation details<\/strong>:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Title<\/strong>: Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson\u2019s disease dementia patients<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Presenter<\/strong>: Maria Maccecchini, Ph.D., President and CEO<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Format<\/strong>: Poster guided tour<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Time of presentation<\/strong>: December 5, 6:15 p.m. PST<\/p>\n<\/li>\n<\/ul>\n<p>The data presented at the meeting will be posted on the Company&#8217;s website following the conference.<\/p>\n<p>The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kpiKD_o4T_htHlTG_npRDSs7ApZS-VSGPGjWzXXmXSpWhDm-0OOUpqL4ZtV24thR7Q7U24GF5WldIPpFE-1G2IJZvwY5XUXRkwsvRD6d_CbOmF-rmjmWI6kfG7W5kyVA_F6VIXzFWOU-XuX0-4iwPg==\" rel=\"nofollow\" target=\"_blank\">PSG Annual Meeting<\/a> brings together leading investigators, coordinators, trainees, advocates, and allied stakeholders to advance collaborative research and showcase the latest advances and best practices in PD.<\/p>\n<p>\n        <strong>About Annovis<\/strong><br \/>\n        <br \/>Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NwX2CB8lyWdKSzoj2rQCyQYBRtb92RHXRF-220xLX_96ESt_oOVnySUmYL8wOHKCArChgyfUimQFHYP_z9STFWsADxdSioRrbWWz6dRVUCgUyr_C113QW6U6QMvAwxv67i0JrC6E5jee7r4gt1bYQws5TX1UQ0xz5iNkElVoVItSmpKdlu1lU3ihwo8eTE97HoRYJxuXCqhI4NteedB6qTW3H6UMyhw_Gc9ALr96lWWuQRu7UPjKUMZPxmESVEBycshjPXOc64SuqHpB1qxVfg==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qqtKJ6guRQTXhngvjc7NITrT-c8kIgcecjrTYhVrWHw-nq7oeBBRJg3HrcRi9VQfAAWoQ-V8IFVGpMAChlmS8m2jewi671QGDspjicCuqfLDXK9CDHIpCcSk8WPCF1c_s_WfqZ0hfdAUq8qZg_4PB2m0xt9llDch6Ej3RNMscxVgT4Rhm6NHWhiJVGVpAPUC_aUWiV3-S_T-AhqprNLtoIxXeeqhMiq5vUAfJHUh-yPSC2MZ90vt1ybVbPxiXpIqC-49649jaBbhemWSlHiDp4vE-29ZAbWBLW1__ADG54wutqovLjfiVbmgmt2wn8TB\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tyOVkYcLHKcXn32m1dbE7q1g8zfveQ0YVk8WWC-WvdzOWz4EEvC3XWj1ENyKOwuGNJ8iouyO0wAWOB-dYCsB2ZNcKOoZl_LJuX66w0P1SZzUsKkp5767sqPzjllnwnb6vF2CHE6ff4x7GMXXoNJT2jXvkKAGdDSp9GHqbSyS3O9ydSR50XSOqL0ZtzUFLpJv4kRfNd3XvhGX_bBMhY8nZcjzSqm76YtC975RmZfEB7c5HK53s0LFPNk-RUuToZCp\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=35XUebq3rNkbYjlUG-smyFtnwaduR-aXHzwhcd6f_p0DguCABq8BbClf4WWrKKKhbWHwB2U-2jYzazfzNhGjnu8zIvlo2GJ4UOk3no_wEfnOQeJ9IEYcQEn21uVouyUX6IrMH3PcS4ZWx2A2aTeaw2nvtFBEqo74wk5whOe0w_BZe-HKWHWYDC7vY6WPPpi4JykE3liqGMaBfejHR4S8fw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Investor Alerts<\/strong><br \/>\n        <br \/>Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U8ADeEWjkyKObapLjAt_WxUpJFFDERZyxKomQQa4yyZs4cJ0QPYpKUBjcRJhNc7jGwXlwd-n--RBrTNF8iDuwFG57a5hF73BL7xUs6XZhW9oMe7Sdr_DrUbXCh7UrIVbM0sZWytM2dmRO7d8lzQTXCfCV_k9AeErbBsk_2bp-L4m0gqo0opSxoslbq9y1KFCbHWxYxAGsX06678dbDNHG5mEEwpJSFBdmUus7ezxRs2emjWG1mVuBtKa3PUrdKxiJ2CjtSFtKp8mf8npjcC5z9BP4py58fuLP6Wyg_EkkaG5jCpGRRDW2SCCskUBCCAa_sjjJI1thIda0T7OOwQL2pKOgUKrJUXd5WPrdv4qLGY=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.annovisbio.com\/email-alerts<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company\u2019s SEC filings under \u201cRisk Factors\u201d in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n<p>\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Annovis Bio Inc.<br \/>101 Lindenwood Drive<br \/>Suite 225<br \/>Malvern, PA 19355<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NwX2CB8lyWdKSzoj2rQCyWDeHvuNyDVSCof19qujLTa8J3ZmUDVPK-gF6jM9W2m62zXVVcCl3hlS2KPhlOCXRSmmeI1svz0w2KyfCNVLJbU9qI3xxUkEK36eQ4VmbrLGhG22GlPYHML7OwwJs4omBJEj-PXaazpss8QL6OcbSyR9G_dijKJziU2mdJ_oia8z7_zX2bDsjnXzPAvTgePTLccMMAG8AF4wQtAfBt_0e5ZssfauW96-f7hzGUoFfUYTXC5JS6E3_FRG0UlzsZdPKg==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Alexander Morin, Ph.D.<br \/>Director, Strategic Communications<br \/>Annovis Bio<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EOWwBWQqdzgQJ_3qEX6odRgU1c0W85j6Chq6XJ7Ew3AY9KC9eUe9YdYsd8XLuie0-Vu7ajnhZqzG38dcjOHlOJbDjzKzk_Iqwbu1vzkD0q_3ztbjoK5mMMkTZTQuN_eMoVAJ4R0jznOUfHYn8kM8p0klpy36JK1WNOpHEBr9lYM6qscMW4sps11wYxSgHt32jSyx_CINPVfMsRiuYNoOrNxc8-cl3b_2OBmGkzy9ukKPTfABScq09XNRVlUaHA56SClt7TCpNP3qfv37EudjLQ==\" rel=\"nofollow\" target=\"_blank\">ir@annovisbio.com<\/a>\u200d<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTExOWQ1OWYtMDk2Ny00YjA2LTlmN2UtZjRmOWUwYmEwMDUyLTEyMDY0MDMtMjAyNS0xMi0wMy1lbg==\/tiny\/Annovis-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. The presentation builds on momentum from the Company\u2019s recent Phase 3 PD biomarker data, showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntanetap also reduces tau biomarkers, which are known to increase with disease severity. The presentation will also debut a cross-study comparison &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915673","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. The presentation builds on momentum from the Company\u2019s recent Phase 3 PD biomarker data, showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntanetap also reduces tau biomarkers, which are known to increase with disease severity. The presentation will also debut a cross-study comparison &hellip; Continue reading &quot;Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T15:34:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group\",\"datePublished\":\"2025-12-03T15:34:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/\"},\"wordCount\":460,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/\",\"name\":\"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=\",\"datePublished\":\"2025-12-03T15:34:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/","og_locale":"en_US","og_type":"article","og_title":"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - Market Newsdesk","og_description":"MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. The presentation builds on momentum from the Company\u2019s recent Phase 3 PD biomarker data, showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntanetap also reduces tau biomarkers, which are known to increase with disease severity. The presentation will also debut a cross-study comparison &hellip; Continue reading \"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-03T15:34:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group","datePublished":"2025-12-03T15:34:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/"},"wordCount":460,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/","name":"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=","datePublished":"2025-12-03T15:34:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc2MiM3MzAyOTA5IzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-to-present-at-the-2025-annual-meeting-of-the-parkinson-study-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915673"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915673\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}